Meeting
2019 ASCO Annual Meeting
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.
Authors
Hirva Mamdani
Karmanos Cancer Institute, Detroit, MI
Hirva Mamdani , Bryan J. Schneider , Laith I. Abushahin , Thomas J Birdas , Kenneth Kesler , Heather Burney , Susan M. Perkins , Shadia Ibrahim Jalal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02639065
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4058)
DOI
10.1200/JCO.2019.37.15_suppl.4058
Abstract #
4058
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani
Poster
2020 ASCO Virtual Scientific Program
Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.
First Author: Hirva Mamdani
Poster
2018 Gastrointestinal Cancers Symposium
A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.
First Author: Hirva Mansurali Mamdani
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Gang Jin